PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS

被引:0
|
作者
Daneshjou, Roxana [1 ]
Zappala, Zachary [1 ]
Kukurba, Kim [1 ]
Boyle, Sean M. [1 ]
Ormond, Kelly E. [1 ]
Klein, Teri E. [1 ]
Snyder, Michael [1 ]
Bustamante, Carlos D. [1 ]
Altman, Russ B. [1 ,2 ]
Montgomery, Stephen B. [1 ,3 ]
机构
[1] Stanford Univ, Dept Genet, Stanford, CA 94061 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94061 USA
[3] Stanford Univ, Dept Pathol, Stanford, CA 94061 USA
关键词
POLYMORPHISM H558R; SPLICE VARIANT; SCN5A; ASSOCIATION; EXPRESSION;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The American College of Medical Genetics and Genomics (ACMG) recently released guidelines regarding the reporting of incidental findings in sequencing data. Given the availability of Direct to Consumer (DTC) genetic testing and the falling cost of whole exome and genome sequencing, individuals will increasingly have the opportunity to analyze their own genomic data. We have developed a web-based tool, PATH-SCAN, which annotates individual genomes and exomes for ClinVar designated pathogenic variants found within the genes from the ACMG guidelines. Because mutations in these genes predispose individuals to conditions with actionable outcomes, our tool will allow individuals or researchers to identify potential risk variants in order to consult physicians or genetic counselors for further evaluation. Moreover, our tool allows individuals to anonymously submit their pathogenic burden, so that we can crowd source the collection of quantitative information regarding the frequency of these variants. We tested our tool on 1092 publicly available genomes from the 1000 Genomes project, 163 genomes from the Personal Genome Project, and 15 genomes from a clinical genome sequencing research project. Excluding the most commonly seen variant in 1000 Genomes, about 20% of all genomes analyzed had a ClinVar designated pathogenic variant that required further evaluation.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 50 条
  • [41] Prevalence and variability in reporting of clinically actionable incidental findings on attenuation-correction CT scans in a veteran population
    B. Julie He
    Brian J. Malm
    Michelle Carino
    Mehran M. Sadeghi
    Journal of Nuclear Cardiology, 2019, 26 : 1688 - 1693
  • [42] Prevalence and variability in reporting of clinically actionable incidental findings on attenuation-correction CT scans in a veteran population
    He, B. Julie
    Malm, Brian J.
    Carino, Michelle
    Sadeghi, Mehran M.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2019, 26 (05) : 1688 - 1693
  • [43] MULTIGENE PANEL TESTING YIELDS HIGH RATES OF CLINICALLY ACTIONABLE VARIANTS AMONGST A LARGE COLORECTAL CANCER COHORT
    Coughlin, Sarah
    Young, Sarah
    Farengo-Clark, Dana
    Heald, Brandie
    Hatchell, Kathryn E.
    Esplin, Edward D.
    Katona, Bryson W.
    GASTROENTEROLOGY, 2022, 162 (07) : S884 - S884
  • [44] Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma
    Lewin, Jeremy
    Garg, Swati
    Lau, Beatrice Y.
    Dickson, Brendan C.
    Traub, Frank
    Gokgoz, Nalan
    Griffin, Anthony M.
    Ferguson, Peter C.
    Andrulis, Irene L.
    Sim, Hao-Wen
    Kamel-Reid, Suzanne
    Stockley, Tracy L.
    Siu, Lillian L.
    Wunder, Jay S.
    Razak, Albiruni R. A.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (01) : 57 - 65
  • [45] Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer (vol 19, pg 114, 2022)
    Petroni, Giulia
    Cantley, Lewis C.
    Santambrogio, Laura
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (04) : 281 - 281
  • [46] Automated reporting of eGFR: a useful tool for identifying and managing kidney disease
    Johnson, David W.
    Jones, Graham R. D.
    Becker, Gavin J.
    Mathew, Timothy H.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (04) : 200 - 203
  • [47] Locus Reference Genomic (LRG): reference resource for the accurate reporting of clinically relevant variants
    Morales, J.
    McMahon, A.
    Gil, L.
    Tully, R.
    Astashyn, A.
    Murphy, T.
    Pruitt, K.
    Maglott, D.
    Cunningham, F.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 710 - 710
  • [48] Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services
    Pasternak, Amy L.
    Ward, Kristen
    Irwin, Madison
    Okerberg, Carl
    Hayes, David
    Fritsche, Lars
    Zoellner, Sebastian
    Virzi, Jessica
    Choe, Hae Mi
    Ellingrod, Vicki
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (02): : 292 - 304
  • [49] Whole Exome Sequencing In Infantile-Onset Pharmaco-Resistant Epilepsy: Novel Mutations And Clinically Actionable Variants
    Damrongphol, P.
    Desudchit, T.
    EPILEPSIA, 2019, 60 : 88 - 88
  • [50] Clinical Implementation of the NextDaySeq Lung Panel for Identification of Clinically Actionable Variants in Non-Small Cell Lung Cancer
    Gao, Jie
    Wu, Huanwen
    Shi, Xiaohua
    Huo, Zhen
    Zhang, Jing
    Liang, Zhiyong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S232 - S232